ArticlebioRxiv : the preprint server for biology2024
MYC is sufficient to generate mid-life high-grade serous ovarian and uterine serous carcinomas in a p53-R270H mouse model.
Alexandra Blackman, Amy C Rees, Robert R Bowers, Christian M Jones, Silvia G Vaena, Madison A Clark, Shelby Carter, Evan D Villamor, Della Evans, Anthony J Emanuel and 6 more
Open access · greenAbstract readPreprint
In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
16 authors at 1 institution in 1 country.
Alexandra BlackmanMedical University of South Carolina.
Amy C ReesMedical University of South Carolina.
Robert R BowersMedical University of South Carolina.
Christian M JonesMedical University of South Carolina.
Silvia G VaenaMedical University of South Carolina.
Madison A ClarkMedical University of South Carolina.
Shelby CarterMedical University of South Carolina.
Evan D VillamorMedical University of South Carolina.
Della EvansMedical University of South Carolina.
Anthony J EmanuelMedical University of South Carolina.
George FullbrightMedical University of South Carolina.
David T LongMedical University of South Carolina.
Laura SpruillMedical University of South Carolina.
Martin J RomeoMedical University of South Carolina.
Kristi L HelkeMedical University of South Carolina.
Medical University of South Carolina · US
Funding
South Carolina IDeA Networks of Biomedical Research (SC INBRE V)P20GM103499 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI EDIE C GOLDSMITH · 2012 to 2026
$61.0MTranslational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RAYMOND N. DUBOIS · 2009 to 2026
$42.7MConnecting BRCA1 functions with DNA crosslink sensitivityR35GM119512 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI LONG, DAVID THOMAS · 2016 to 2025
$3.9MCellular, Biochemical and Molecular Sciences Training Program: Developing the skills and expertise needed for a changing biomedical landscapeT32GM132055 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Amy D Bradshaw, John P O'Bryan · 2019 to 2026
$3.9MTumor suppressor vulnerability conferred by aneuploid loss of haploinsufficient metallothionein genesDP2CA280626 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Joe R Delaney · 2022 to 2026
$2.3MCopy Number Alterations in Low Mutation CancerR00CA207729 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DELANEY, JOE R · 2019 to 2021
$730kCopy Number Alterations in Low Mutation CancerK99CA207729 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DELANEY, JOE R · 2017 to 2018
$230kNCI NIH HHS DP2 CA280626NCI NIH HHS K99 CA207729NCI NIH HHS P30 CA138313NCI NIH HHS R00 CA207729NIGMS NIH HHS P20 GM103499NIGMS NIH HHS R35 GM119512NIGMS NIH HHS T32 GM132055
6 · The paper itselfAbstract
Genetically engineered mouse models (GEMM) have fundamentally changed how ovarian cancer etiology, early detection, and treatment is understood. However, previous GEMMs of high-grade serous ovarian cancer (HGSOC) have had to utilize genetics rarely or never found in human HGSOC to yield ovarian cancer within the lifespan of a mouse.
Indexed as
genetically engineered mouse modelhigh-grade serous ovarian cancerMYConcogenesisOvarian carcinomap53spontaneous cancersyngeneic cancer modeluterine serous cancer
Identifiers
PMID38352443
PMCPMC10862747
OpenAlexW4391311419
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390